Esperion Therapeutics (ESPR) Aandelenoverzicht
Esperion Therapeutics, Inc., een biofarmaceutisch bedrijf, ontwikkelt en verkoopt geneesmiddelen voor de behandeling van patiënten met een verhoogd lipoproteïnecholesterol met lage dichtheid (LDL-C) in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 1/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
ESPR Community Fair Values
Create NarrativeSee what 35 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Esperion Therapeutics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$3.16 |
| 52 Week Hoogtepunt | US$4.18 |
| 52 Week Laag | US$1.10 |
| Bèta | 1.06 |
| 1 maand verandering | 0.96% |
| 3 maanden verandering | 35.62% |
| 1 Jaar Verandering | 170.09% |
| 3 jaar verandering | 96.27% |
| 5 jaar verandering | -82.75% |
| Verandering sinds IPO | -78.21% |
Recent nieuws en updates
Narratiefupdate • Jun 22
ESPR: Downgrades And Pending ArchiMed Deal Will Shape Balanced Forward Outlook
Esperion Therapeutics' updated analyst price target has shifted from about $6.50 to roughly $3.20, as analysts point to revised assumptions for revenue growth, profit margins, and future P/E multiples following a recent wave of downgrades. Analyst Commentary Recent Street research on Esperion Therapeutics clusters around a series of downgrades, with analysts reassessing how the company executes on its growth plans and what that could mean for valuation.
Narratiefupdate • Jun 04
ESPR: Vision 2040 Execution And Corstasis Integration Will Offset Recent Downgrades
Esperion Therapeutics' updated analyst price target holds at $3.16 per share, as analysts weigh a higher discount rate and softer revenue growth assumptions against slightly better profit margin expectations and a modestly lower future P/E, all set against recent downgrades and an earlier move by Citizens to raise its target to $5 from $4 on continued execution of the Vision 2040 plan. Analyst Commentary Recent Street research on Esperion has shifted in a clearly more cautious direction, with several bearish analysts moving to less constructive ratings even as the average price target holds near US$3.16 per share.
Narratiefupdate • May 19
ESPR: Vision 2040 Plans And Acquisition Are Weighed Against Downgrade Risks
Esperion Therapeutics' updated analyst price target has moved from about $15.92 to $3.28 as analysts factor in a series of recent downgrades alongside mixed sentiment around execution on longer term plans and pipeline expansion. Analyst Commentary Recent research has been dominated by downgrades, but there are still a few points that bullish analysts highlight when they look at Esperion Therapeutics and its current valuation.Recent updates
Narratiefupdate • Jun 22
ESPR: Downgrades And Pending ArchiMed Deal Will Shape Balanced Forward Outlook
Esperion Therapeutics' updated analyst price target has shifted from about $6.50 to roughly $3.20, as analysts point to revised assumptions for revenue growth, profit margins, and future P/E multiples following a recent wave of downgrades. Analyst Commentary Recent Street research on Esperion Therapeutics clusters around a series of downgrades, with analysts reassessing how the company executes on its growth plans and what that could mean for valuation.Narratiefupdate • Jun 04
ESPR: Vision 2040 Execution And Corstasis Integration Will Offset Recent Downgrades
Esperion Therapeutics' updated analyst price target holds at $3.16 per share, as analysts weigh a higher discount rate and softer revenue growth assumptions against slightly better profit margin expectations and a modestly lower future P/E, all set against recent downgrades and an earlier move by Citizens to raise its target to $5 from $4 on continued execution of the Vision 2040 plan. Analyst Commentary Recent Street research on Esperion has shifted in a clearly more cautious direction, with several bearish analysts moving to less constructive ratings even as the average price target holds near US$3.16 per share.Narratiefupdate • May 19
ESPR: Vision 2040 Plans And Acquisition Are Weighed Against Downgrade Risks
Esperion Therapeutics' updated analyst price target has moved from about $15.92 to $3.28 as analysts factor in a series of recent downgrades alongside mixed sentiment around execution on longer term plans and pipeline expansion. Analyst Commentary Recent research has been dominated by downgrades, but there are still a few points that bullish analysts highlight when they look at Esperion Therapeutics and its current valuation.Narratiefupdate • May 04
ESPR: Vision 2040 And Corstasis Deal Will Balance Downgrade Concerns
Narrative Update on Esperion Therapeutics The updated analyst price target for Esperion Therapeutics has moved closer to recent Street views, rising from a fair value estimate of $1.78 to $3.16. Analysts are weighing recent downgrades against research that cites consistent Q4 results, progress on the Vision 2040 plan, and pipeline expansion, including the Corstasis Therapeutics acquisition and ESP-2001 advancement.Narratiefupdate • Apr 20
ESPR: Vision 2040 Progress Will Likely Mask Corstasis Execution Risk
Analysts recently lifted their price target on Esperion Therapeutics to $5 from $4, citing Q4 results that aligned with earlier guidance and continued progress on the Vision 2040 plan, including the Corstasis Therapeutics acquisition and advancement of ESP-2001. Analyst Commentary Recent commentary around Esperion focuses on how the updated US$5 price target lines up with the company’s execution on its Vision 2040 plan.Narratiefupdate • Apr 06
ESPR: Vision 2040 And Corstasis Deal Will Likely Expose Execution Risks
Analysts raised their price target on Esperion Therapeutics to $5 from $4, citing the company's Q4 results, continued execution of its Vision 2040 plans, the acquisition of Corstasis Therapeutics, and progress with ESP-2001 as key reasons for the update. Analyst Commentary The latest research update highlights that the higher US$5 price target reflects Q4 results that were in line with January guidance, along with continued execution of the Vision 2040 plans.Narratiefupdate • Mar 23
ESPR: Vision 2040 Execution And ESP-2001 Progress Will Drive Future Upside
Narrative Update Overview Analysts have lifted their price target on Esperion Therapeutics to $5, up from $4, citing continued execution on Vision 2040, the Corstasis Therapeutics acquisition, and progress with ESP-2001 as key drivers behind the updated valuation inputs. These inputs include a higher fair value estimate and adjusted discount rate and P/E assumptions.Narratiefupdate • Mar 09
ESPR: Patent Litigation Outcomes Will Likely Expose Weak Profitability Execution Risks
Analysts have revised their price target for Esperion Therapeutics to align with updated assumptions that keep fair value steady at about $1.78 per share. This reflects higher modeled revenue growth, balanced by lower projected profit margins and a slightly reduced future P/E multiple.Narratiefupdate • Feb 22
ESPR: Overweight Rating Will Likely Conceal Risk Around Patent And Profitability Execution
Analysts have adjusted their price target on Esperion Therapeutics to $9, reflecting updated assumptions for revenue growth, profit margin, and forward P/E. This change is supported by recent Street research highlighting the new coverage and target level.Narratiefupdate • Feb 08
ESPR: Overweight Rating Will Likely Mask Execution Risk Around Acquisition Strategy
Analysts have raised their price target for Esperion Therapeutics to about US$1.78 from roughly US$1.72, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E. These changes reflect the recent US$9 initiation from Piper Sandler as part of a broader reassessment of the stock's earnings power and risk profile.Narratiefupdate • Jan 24
ESPR: Overweight Rating And Accretive Deal Hunt Will Support Bullish Sentiment
Analysts have nudged their price target for Esperion Therapeutics slightly higher to around US$6.50, citing updated assumptions for revenue growth, profit margin and future P/E that are generally consistent with recent Street research, including the new US$9 target from Piper Sandler. Analyst Commentary Analysts are using the new US$9 reference point to frame both the upside case and the key execution questions around Esperion Therapeutics, with the latest work focusing on how current assumptions for revenue, profit margin and future P/E might play out over time.Narratiefupdate • Jan 07
ESPR: Overweight Rating Will Likely Obscure Persistent Execution And Profitability Risks
Narrative Update on Esperion Therapeutics Analysts have lifted their price target on Esperion Therapeutics to US$9, citing updated assumptions for revenue growth, profitability, and future P/E that reflect a more constructive view of the company’s earnings potential. Analyst Commentary Recent coverage highlights a more constructive stance on Esperion Therapeutics, with a US$9 price target used as a reference point for what the business might be worth if current assumptions on revenue and earnings play out as expected.Narratiefupdate • Dec 23
ESPR: Rising Street Optimism Will Likely Mask Lingering Execution Risks
Analysts have raised their price target on Esperion Therapeutics to $9.00 from $7.00, reflecting increased confidence in the stock's valuation despite moderating long term growth and margin assumptions. Analyst Commentary Recent Street research has reflected a cautiously optimistic stance toward Esperion Therapeutics, with new coverage and revised price targets coalescing around the $9 level.Narratiefupdate • Dec 09
ESPR: Rising Overweight Ratings Will Support Bullish Sentiment Toward Shares
Analysts have nudged their price target for Esperion Therapeutics higher to approximately $6.50 per share from about $6.15, citing supportive Street research, including recent Overweight initiations and target increases. These changes reflect confidence in the company’s longer term earnings multiple despite slightly tempered growth and margin assumptions.Narratiefupdate • Nov 25
ESPR: Overweight Ratings And Positive Developments Will Strengthen Bullish Outlook For Shares
Analysts have raised their price target for Esperion Therapeutics from $7 to $9 per share. This reflects improved expectations for the company's revenue growth and fair value based on recent positive coverage and outlook updates.Narratiefupdate • Nov 09
ESPR: Price Target Increase Will Drive Renewed Confidence In Future Performance
Analysts have raised their price target for Esperion Therapeutics from $7 to $9, citing improved growth and profitability expectations. Analyst Commentary Bullish Takeaways Bullish analysts have increased their price targets, reflecting growing confidence in the company's outlook and execution capabilities.Seeking Alpha • Sep 09
Esperion: A Mixture Of Opportunity And Risk: Why I Would Hold For Now
Summary Esperion's stock surged over 30% this month after Q2 results beat expectations, driven by strong U.S. sales and global partnerships. The company benefits from high-margin collaboration revenues and expanding international milestones but faces heavy debt and declining cash reserves. Patent settlements protect U.S. exclusivity through 2040, yet ongoing litigation and financial strain add significant risk to the investment thesis. Given the mix of opportunity and risk, I assign a Hold rating until Esperion demonstrates consistent profitability and improved financial stability. Read the full article on Seeking AlphaNarratiefupdate • Aug 06
Rising Digital Adoption And Global Partnerships Will Shape Future Markets
Esperion Therapeutics' consensus price target has increased as analysts now assign a higher future P/E despite a decline in net profit margin, resulting in the APT rising from $5.79 to $6.50. What's in the News Esperion Therapeutics was dropped from the S&P Pharmaceuticals Select Industry Index.
Nieuw narratief • May 04
US FDA Approvals And Global Expansion Will Shape Future Markets
International expansion and strategic partnerships are anticipated to significantly boost global sales and royalty revenues over time.Seeking Alpha • Feb 22
Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug
Summary Esperion Therapeutics has two approved LDL-C lowering therapies, Nexletol and Nexlizet, but lacks a strong pipeline for future growth. Recent label expansions for Nexletol and Nexlizet have broadened their indications, but competition from Merck's PCSK9 inhibitor could impact ESPR's market position. Financially, Esperion has limited cash runway and faces challenges from more effective and safer LDL-C lowering treatments like PCSK9 inhibitors. Despite trading near 52-week lows, I see little upside in investing in Esperion due to its moderate benefits and lack of a robust pipeline. Read the full article on Seeking AlphaSeeking Alpha • Dec 08
Will The Long Awaited Breakout For Esperion Therapeutics Hold?
Summary Esperion Therapeutics' stock broke out above a year-long trading range, signaling a potential sustainable breakout if support at $3.40 holds. Despite past skepticism and price fades, recent technical achievements and strategic moves, including global drug submissions, bolster the stock's outlook. The Piper Sandler Conference reinforced Esperion's growth strategy, with CEO Sheldon Koenigand CFO Ben Halladay providing encouraging news on guidance and business performance. Insider ownership remains low, which could impact confidence, but the company's strategic positioning and milestones present a compelling investment case. Read the full article on Seeking AlphaSeeking Alpha • Nov 13
Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy
Summary I maintain my buy rating on Esperion Therapeutics due to its strong Q3 2024 financial performance, showcasing consistent revenue growth and market adoption. The Company's aggressive commercialization efforts, including market coverage expansion and sales force growth, have significantly boosted retail prescriptions and broadened future revenue streams. International expansion through partnerships with Daiichi Sankyo Europe and Otsuka Pharmaceutical has driven prescription and revenue growth, strengthening ESPR's global presence. Technical analysis indicates bullish momentum with no signs of reversal, supported by positive financials and key growth drivers, making ESPR a buy. Read the full article on Seeking AlphaSeeking Alpha • Aug 16
Esperion Therapeutics: Strategically Positioned To Grow
Summary Esperion is a pharmaceutical firm whose focus is to treat patients with high low-density lipoprotein cholesterol (LDL-C). I rate it a buy due to strategic initiatives and market potential driving significant growth. Strong revenue growth and margin expansions reflect improving financial performance and market breakthrough. ESPR's unique non-statin medicines address unmet demand, offering a competitive advantage in the large and growing LDL-C-lowering pharmaceutical market. Read the full article on Seeking AlphaSeeking Alpha • May 20
Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
Summary Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism. The company's Q1 showed accelerating revenue growth, but guidance offered little new information. A lipid lurker marketing campaign shows early top of the funnel success, but there is little data yet to demonstrate bottom funnel performance. Still, with the stock trading at a valuation discount, I continue to buy ESPR in expectation of significant upside once the company shows evidence of exponential growth and healthy profitability. Read the full article on Seeking AlphaSeeking Alpha • Feb 28
A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics
Summary Esperion Therapeutics reported strong Q4 and full-year revenue growth, with total revenue increasing 72% YoY to $32.3M in Q4 and 54% YoY to $116M for the full year. The company expects a true inflection point after receiving approval for expanded labels for its cardiovascular drugs. Esperion is preparing for a significant sales ramp starting in April, with an expanded sales force and an anticipated larger patient population. Read the full article on Seeking AlphaSeeking Alpha • Jan 22
Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations
Summary Esperion Therapeutics' stock gapped down after news of a stock offering but fortunately never reached the $1.50 offering price. The presentation at the JP Morgan Healthcare Conference provided little new information and failed to boost the stock. The Q&A session provided some insights, including information about utilization management headwinds and the company's digital consumer campaign. Altogether, the company appears to be stuck in a "prove it" box and needs to demonstrate a compelling path to profitability to maintain interest in investing in the promise of its drugs. Read the full article on Seeking AlphaSeeking Alpha • Jan 14
Esperion Is Sitting On A Potential Blockbuster Drug
Summary Esperion Therapeutics has a potential blockbuster drug that is gaining traction among the medical community. The company's main drugs, NEXLIZET and NEXLETOL, have been approved by the FDA and offer alternatives to statins for lowering LDL cholesterol. Recent developments, including an expanded labeling and influential endorsements from doctors like Peter Attia, suggest potential growth for the company. Read the full article on Seeking AlphaAnalyseartikel • Jun 19
Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Esperion Therapeutics, Inc.'s ( NASDAQ:ESPR ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy...Rendement voor aandeelhouders
| ESPR | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 0% | -1.3% | 0.8% |
| 1Y | 170.1% | 47.9% | 20.2% |
Rendement versus industrie: ESPR overtrof de US Pharmaceuticals industrie, die het afgelopen jaar een rendement 47.9 % opleverde.
Rendement versus markt: ESPR overtrof de US markt, die het afgelopen jaar een rendement opleverde van 20.2 %.
Prijsvolatiliteit
| ESPR volatility | |
|---|---|
| ESPR Average Weekly Movement | 16.4% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: De aandelenkoers van ESPR is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 16% ) van ESPR is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2008 | 294 | Sheldon Koenig | www.esperion.com |
Esperion Therapeutics, Inc., een biofarmaceutisch bedrijf, ontwikkelt en verkoopt geneesmiddelen voor de behandeling van patiënten met een verhoogd lipoproteïnecholesterol met lage dichtheid (LDL-C) in de Verenigde Staten. Tot de producten die het bedrijf op de markt brengt behoren NEXLETOL (bempedoëzuur) en NEXLIZET (bempedoëzuur en ezetimibe) tabletten, orale, eenmaal daagse, niet-statinehoudende geneesmiddelen voor de behandeling van primaire hyperlipidemie bij volwassenen met heterozygote familiaire hypercholesterolemie en hart- en vaatziekten die extra verlaging van LDL-C nodig hebben. Haar producten omvatten ook NILEMDO, een ATP Citrate Lyase (ACL) remmer die LDL-C en cardiovasculair risico verlaagt door de biosynthese van cholesterol te verminderen en de LDL-receptoren te upreguleren; en NUSTENDI, een bempedinezuur en ezetimibe tablet voor de behandeling van verhoogde LDL-C.
Esperion Therapeutics, Inc. Samenvatting
| ESPR fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$810.91m |
| Inkomsten(TTM) | -US$7.42m |
| Inkomsten(TTM) | US$418.24m |
1.9x
P/S-verhouding-109.6x
Koers/WinstverhoudingIs ESPR overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ESPR resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$418.24m |
| Kosten van inkomsten | US$176.54m |
| Brutowinst | US$241.70m |
| Overige uitgaven | US$249.13m |
| Inkomsten | -US$7.42m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.029 |
| Brutomarge | 57.79% |
| Nettowinstmarge | -1.77% |
| Schuld/Eigen Vermogen Verhouding | -175.8% |
Hoe presteerde ESPR op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/07 00:49 |
| Aandelenkoers aan het einde van de dag | 2026/07/07 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Esperion Therapeutics, Inc. wordt gevolgd door 16 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jason Zemansky | BofA Global Research |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Jason Butler | Citizens JMP Securities, LLC |